Page last updated: 2024-08-24

pivalyloxymethyl butyrate and imatinib mesylate

pivalyloxymethyl butyrate has been researched along with imatinib mesylate in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Belyaeva, I; Merkin, V; Rabizadeh, E; Shaklai, M; Zimra, Y	1

Other Studies

1 other study(ies) available for pivalyloxymethyl butyrate and imatinib mesylate

Article	Year
Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line. Leukemia research, 2007, Volume: 31, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Butyrates; Cell Cycle; Cell Differentiation; Cell Survival; Drug Synergism; Enzyme Inhibitors; Erythroid Cells; Flow Cytometry; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Immunoblotting; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2007

Article

Year

Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line.

Leukemia research, 2007, Volume: 31, Issue:8

Topics: Antineoplastic Agents; Apoptosis; Benzamides; Butyrates; Cell Cycle; Cell Differentiation; Cell Survival; Drug Synergism; Enzyme Inhibitors; Erythroid Cells; Flow Cytometry; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Immunoblotting; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2007